Larry Ajuwon

Sep 12, 2024 | clinicalleader.com | Larry Ajuwon

By Larry Ajuwon, RHIEOS-Ventures and Dealligence Developing new medicines in the clinical trial industry relies on the coming together of many organizations. But what can three tools — a notebook, a chronodex, and a compendium — teach us about the essential aspects of successful negotiation and collaboration? Though these tools are seemingly ordinary and perhaps often overlooked, they encapsulate the principles of preparation, planning, and knowledge — all crucial in any negotiation.

Jan 22, 2024 | clinicalleader.com | Larry Ajuwon |Kerry Leyden |Caroline Potts |Devra Densmore

YPrime unveils a transformative brand focused on Solving for Certainty in clinical trials. Experience the reimagined brand and explore the solutions that transform clinical research at www.yprime.com. New Calculator Could Help Determine Costs And Fair CompensationPatients, sponsors, and other stakeholders could finally get help estimating patients' cost burdens thanks to the industry’s first open-access financial burden calculator. Will FDORA Impact My Clinical Research Practice?

Dec 14, 2023 | clinicalleader.com | Kamila Novak |Larry Ajuwon

By Larry Ajuwon, director at Rhieos-Ventures and lead partner at TrialValue Clinical trials come with benefits, risks, and costs that influence a patient’s decision to participate and affect their conduct during and after the trial. Financial, in addition to logistical, burdens have been shown to affect recruitment, access to study sites, and completion rate1.